NDAORALTABLET
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
DETROL (tolterodine tartrate) by Viatris is clinical pharmacology tolterodine is a competitive muscarinic receptor antagonist. First approved in 1998.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DETROL (tolterodine tartrate) is an oral small-molecule muscarinic receptor antagonist approved in 1998 for overactive bladder (OAB) management. It works by competitively blocking cholinergic muscarinic receptors to reduce urinary bladder contractions and urinary frequency. Both tolterodine and its active 5-hydroxymethyl metabolite contribute to therapeutic effect via high-specificity muscarinic antagonism.
$0.099BPart D
LOE ApproachingDETROL is in late-stage lifecycle maturity with modest Part D utilization, suggesting a consolidating brand team focused on retention and generic transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl…
Worked on DETROL at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.